WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Lawyer for former top lawmaker in Michigan House expects he will be chargedThe US ambassador to Japan says boosting arms industry ties is key to a stronger security allianceA top Federal Reserve official opens door to keeping rates high for longerPalestinian death toll in Gaza rises to 33,729: MinistryCoverage of China's basic medical insurance stableChinese lawmakers submit 298 proposals to annual legislative sessionChinese FM meets with Vietnamese counterpartBelgian police shut down a far right conference as it rallies ahead of Europe's June electionsXi's article on cultural heritage, fine traditional Chinese culture to be publishedCharlize Theron brings along adorable daughter August, 7, to sit front row at Dior's pre
3.0737s , 6496.1015625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Wave news portal